SpringWorks Therapeutics (SWTX) Shares Soar 3.95% After Analyst Upgrades

SpringWorks Therapeutics (SWTX) shares surged by 3.95% today, marking a significant rebound after the stock price plummeted to its lowest level since January 2025, with an intraday decline of 8.06%.

Analysts have been actively revising their target prices and ratings for SpringWorks Therapeutics, which has had a notable impact on investor sentiment. Evercore ISI recently boosted their target price for the company's shares from $60 to $65, while maintaining a buy rating. This adjustment reflects a positive outlook on the company's future prospects and has likely contributed to the recent surge in stock price. Similarly, BofA Securities analyst Alec Stranahan has also maintained a buy rating for SpringWorks Therapeutics, setting a target price of $55. These analyst actions are crucial in shaping market expectations and can drive significant movements in the stock price.